Paris – 10 July 2015– EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for small and medium-sized companies (SMEs),today celebrated the listing of Biocorp, a French company specialised in developing and manufacturing innovative medical and drug delivery devices. Biocorp is listed on Alternext Paris.
Biocorp is a French company that develops, manufactures and markets innovative medical devices for the pharmaceutical industry. Based in Issoire, near Clermont-Ferrand in central France, Biocorp was founded in 2004 and has been awarded BIP’s “Innovative Company” label. From the start, it has combined production of devices for leading pharmaceutical players—generating a stream of recurring income—with active R&D in medical devices, in particular seal and reconstitution systems. At the instigation of founder Jacques Gardette, Biocorp acquired a software/data encryption and management business in 2013 to develop the very first connected injection systems. Its first product is DataPen, the first smart injector pen connected to the internet, whose prime market is the treatment of diabetes.
Biocorp (ticker code: ALCOR) was listed through the admission to trading on 10 July 2015 of the 2,957,867 ordinaryshares making up its equity, including 957,867new shares issued through a Global Offering.
The admission and issue price of Biocorp shares was set at €9.25per share. Market capitalisation was around €27,360,270on the day of listing, and the total amount raised was €8,860,270million.
Jacques Gardette, Biocorp’s founder, chairman & CEO, said:“Our successful listing gives us the resources we need to deploy our strategy quickly and achieve several critical milestones, including new contracts, expansion on international markets and a ramp-up of production capacity. Listing will also raise our profile and facilitate agreements with international partners. I would like to thank all of our employees and partners, along with our new shareholders, for their confidence.”
Eric Forest, CEO of EnterNext, said: “We are delighted to welcome Biocorp, a medtech company based in Auvergne, as it lists on Alternext. EnterNext has helped many medtech businesses secure the funding they need through financial markets to accelerate their business development. Listing will give Biocorp resources to beef up its R&D, which is at the core of its business, and to ramp up its production capacity. Biocorp is the 23rd SME IPO on our markets in 2015, confirming investor appetite for medium sized companies since the beginning of the year.”